@TIME @nytimes @latimes ... she should be on the cover of every #time-based magazine!!! #NobWorthyAchievement !!!!
RT @AlMusella: @JoeBiden @DrBiden did you see the news about breakthrough in glioblastoma treatment? Dcvax. https://t.co/sowFiBVVhA we ne…
$NWBO
RT @AlMusella: @JoeBiden @DrBiden did you see the news about breakthrough in glioblastoma treatment? Dcvax. https://t.co/sowFiBVVhA we ne…
RT @AlMusella: @JoeBiden @DrBiden did you see the news about breakthrough in glioblastoma treatment? Dcvax. https://t.co/sowFiBVVhA we ne…
@POTUS
RT @AlMusella: @JoeBiden @DrBiden did you see the news about breakthrough in glioblastoma treatment? Dcvax. https://t.co/sowFiBVVhA we ne…
RT @joostverhoeff: Promising Overall Survival results from Phase 3 trial of Dendritic Cell Vaccination With Extension of Survival Among Pat…
RT @EveryTrade: $NWBO https://t.co/CZiCWtBvk1
RT @joostverhoeff: Promising Overall Survival results from Phase 3 trial of Dendritic Cell Vaccination With Extension of Survival Among Pat…
RT @shawna11lee: Now the world can know what @NorthwestBio has known all along. $nwbo #cancercure @POTUS @drsanjaygupta @Merck #dcvax #murc…
RT @HenryMuney: JAMA article is published and Dr. Linda Liau interview! $NWBO #DCVax-L 1. https://t.co/pfRDJSM1lP 2. https://t.co/O1rkNG8t…
@POTUS @WhiteHouse @VP FYI. #CancerMoonshot.
RT @AlMusella: @JoeBiden @DrBiden did you see the news about breakthrough in glioblastoma treatment? Dcvax. https://t.co/sowFiBVVhA we ne…
RT @AlMusella: @JoeBiden @DrBiden did you see the news about breakthrough in glioblastoma treatment? Dcvax. https://t.co/sowFiBVVhA we ne…
RT @AlMusella: @JoeBiden @DrBiden did you see the news about breakthrough in glioblastoma treatment? Dcvax. https://t.co/sowFiBVVhA we ne…
RT @AlMusella: @JoeBiden @DrBiden did you see the news about breakthrough in glioblastoma treatment? Dcvax. https://t.co/sowFiBVVhA we ne…
RT @FlemmingBruce: $NWBO Just hand her that goddamn prize!!!
RT @AlMusella: @JoeBiden @DrBiden did you see the news about breakthrough in glioblastoma treatment? Dcvax. https://t.co/sowFiBVVhA we ne…
RT @AlMusella: @JoeBiden @DrBiden did you see the news about breakthrough in glioblastoma treatment? Dcvax. https://t.co/sowFiBVVhA we ne…
RT @AlMusella: @JoeBiden @DrBiden did you see the news about breakthrough in glioblastoma treatment? Dcvax. https://t.co/sowFiBVVhA we ne…
RT @AlMusella: @JoeBiden @DrBiden did you see the news about breakthrough in glioblastoma treatment? Dcvax. https://t.co/sowFiBVVhA we ne…
RT @AXuring2: 100% Linda Liau. @TIME #PersonoftheYear $NWBO please retweet so @TIME hears
RT @HenryMuney: Neuro-oncologist Linda Liau, MD, PhD, MBA led brain tumor vaccine trials with success and clinically meaningful benefit. Li…
100% Linda Liau. @TIME #PersonoftheYear $NWBO please retweet so @TIME hears
RT @AlMusella: @JoeBiden @DrBiden did you see the news about breakthrough in glioblastoma treatment? Dcvax. https://t.co/sowFiBVVhA we ne…
RT @joostverhoeff: Promising Overall Survival results from Phase 3 trial of Dendritic Cell Vaccination With Extension of Survival Among Pat…
RT @joostverhoeff: Promising Overall Survival results from Phase 3 trial of Dendritic Cell Vaccination With Extension of Survival Among Pat…
RT @Dr_Alex_Crimi: #Brain #Cancer #Vaccine Shown To Relatively Extend Patient Survival: "Association of Autologous Tumor Lysate-Loaded Dend…
RT @joostverhoeff: Promising Overall Survival results from Phase 3 trial of Dendritic Cell Vaccination With Extension of Survival Among Pat…
RT @FlemmingBruce: $NWBO Just hand her that goddamn prize!!!
RT @HenryMuney: Neuro-oncologist Linda Liau, MD, PhD, MBA led brain tumor vaccine trials with success and clinically meaningful benefit. Li…
@JoeBiden @DrBiden did you see the news about breakthrough in glioblastoma treatment? Dcvax. https://t.co/sowFiBVVhA we need your help getting FDA approval speededup! #gbm #dcvax
RT @HenryMuney: Neuro-oncologist Linda Liau, MD, PhD, MBA led brain tumor vaccine trials with success and clinically meaningful benefit. Li…
5. Cancer vaccine trials and developments: P3 DCVax-L/SOC mOS nGBM (19.3/16.5m) rGBM (13.2/7.8m). P1b/2a in rGBM (ROSALIE), and P2 nGBM SurVaxM/TMZ (SURVIVE), multi-lamellar mRNA-nanoparticle vaccines, iPSC-derived NK cell cancer immunotherapy. https://t
RT @FlemmingBruce: $NWBO #LindaLiau Nobel Prize lady in her shining moment ❤️
RT @roelverhaak: Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Ne…
RT @jman4956: #LindaLiau
RT @FlemmingBruce: $NWBO Just hand her that goddamn prize!!!
#Brain #Cancer #Vaccine Shown To Relatively Extend Patient Survival: "Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent #Glioblastoma" https://t.co/Uq4fHRZ8
RT @jman4956: #LindaLiau
RT @roelverhaak: Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Ne…
RT @jman4956: #LindaLiau
RT @roelverhaak: Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Ne…
RT @Eti8888: $NWBO
RT @FlemmingBruce: $NWBO Just hand her that goddamn prize!!!
RT @MDCearns: Hot off the press 4 hours ago… Trial evidence of survival benefit particularly for recurrent #glioblastoma from a dendritic…
RT @roelverhaak: Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Ne…
RT @FlemmingBruce: $NWBO Just hand her that goddamn prize!!!
@m17au_aussie17 A great new immunotherapy treatment intent on changing the current paradigm https://t.co/VEClC64M9D
We should all take some time for careful consideration and review. But, it does signal some exciting directions in brain tumor treatment!
$NWBO Just hand her that goddamn prize!!!
RT @NicholasBlondin: “The mOS for patients with nGBM assigned to the DCVax-L cohort at enrollment was 19.3 months from the time of randomiz…
RT @HenryMuney: Neuro-oncologist Linda Liau, MD, PhD, MBA led brain tumor vaccine trials with success and clinically meaningful benefit. Li…
RT @FlemmingBruce: $NWBO #LindaLiau Nobel Prize lady in her shining moment ❤️
RT @NicholasBlondin: “The mOS for patients with nGBM assigned to the DCVax-L cohort at enrollment was 19.3 months from the time of randomiz…
RT @NicholasBlondin: “The mOS for patients with nGBM assigned to the DCVax-L cohort at enrollment was 19.3 months from the time of randomiz…
RT @roelverhaak: Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Ne…
@BWalkerTTAGGG @Nina_kd @FlemmingBruce @biggercapital @SNO https://t.co/lPm1oAG6cN As it turns out you were wrong about the 2nd point, and you are wrong about the 1st … https://t.co/u1vmLcJSQ4
RT @joostverhoeff: Promising Overall Survival results from Phase 3 trial of Dendritic Cell Vaccination With Extension of Survival Among Pat…
RT @NicholasBlondin: “The mOS for patients with nGBM assigned to the DCVax-L cohort at enrollment was 19.3 months from the time of randomiz…
RT @HenryMuney: Neuro-oncologist Linda Liau, MD, PhD, MBA led brain tumor vaccine trials with success and clinically meaningful benefit. Li…
RT @joostverhoeff: Promising Overall Survival results from Phase 3 trial of Dendritic Cell Vaccination With Extension of Survival Among Pat…
RT @HenryMuney: Neuro-oncologist Linda Liau, MD, PhD, MBA led brain tumor vaccine trials with success and clinically meaningful benefit. Li…
RT @HenryMuney: Neuro-oncologist Linda Liau, MD, PhD, MBA led brain tumor vaccine trials with success and clinically meaningful benefit. Li…
RT @NicholasBlondin: “The mOS for patients with nGBM assigned to the DCVax-L cohort at enrollment was 19.3 months from the time of randomiz…
RT @JonksStonks: Dr. Linda Liau https://t.co/F3W3UYnnZb Enough said.
RT @roelverhaak: Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Ne…
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial | @JAMA Network @NWBO https://t.co/
RT @HenryMuney: Neuro-oncologist Linda Liau, MD, PhD, MBA led brain tumor vaccine trials with success and clinically meaningful benefit. Li…
$NWBO
RT @NicholasBlondin: “The mOS for patients with nGBM assigned to the DCVax-L cohort at enrollment was 19.3 months from the time of randomiz…
RT @HenryMuney: Neuro-oncologist Linda Liau, MD, PhD, MBA led brain tumor vaccine trials with success and clinically meaningful benefit. Li…
RT @apwriter: $nwbo
RT @JAMAOnc: This study found that autologous tumor lystate-loaded dendritic cell vaccination plus standard of care (SOC) was associated wi…
RT @HenryMuney: Neuro-oncologist Linda Liau, MD, PhD, MBA led brain tumor vaccine trials with success and clinically meaningful benefit. Li…
RT @HenryMuney: Neuro-oncologist Linda Liau, MD, PhD, MBA led brain tumor vaccine trials with success and clinically meaningful benefit. Li…
RT @roelverhaak: Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Ne…
RT @HenryMuney: Neuro-oncologist Linda Liau, MD, PhD, MBA led brain tumor vaccine trials with success and clinically meaningful benefit. Li…
RT @HenryMuney: Neuro-oncologist Linda Liau, MD, PhD, MBA led brain tumor vaccine trials with success and clinically meaningful benefit. Li…
RT @HenryMuney: Neuro-oncologist Linda Liau, MD, PhD, MBA led brain tumor vaccine trials with success and clinically meaningful benefit. Li…
RT @NicholasBlondin: “The mOS for patients with nGBM assigned to the DCVax-L cohort at enrollment was 19.3 months from the time of randomiz…
RT @HenryMuney: Neuro-oncologist Linda Liau, MD, PhD, MBA led brain tumor vaccine trials with success and clinically meaningful benefit. Li…
RT @HenryMuney: Neuro-oncologist Linda Liau, MD, PhD, MBA led brain tumor vaccine trials with success and clinically meaningful benefit. Li…
RT @NicholasBlondin: “The mOS for patients with nGBM assigned to the DCVax-L cohort at enrollment was 19.3 months from the time of randomiz…
RT @joostverhoeff: Promising Overall Survival results from Phase 3 trial of Dendritic Cell Vaccination With Extension of Survival Among Pat…
RT @NicholasBlondin: “The mOS for patients with nGBM assigned to the DCVax-L cohort at enrollment was 19.3 months from the time of randomiz…
RT @FlemmingBruce: $NWBO #LindaLiau Nobel Prize lady in her shining moment ❤️
RT @HenryMuney: Neuro-oncologist Linda Liau, MD, PhD, MBA led brain tumor vaccine trials with success and clinically meaningful benefit. Li…
RT @HenryMuney: Neuro-oncologist Linda Liau, MD, PhD, MBA led brain tumor vaccine trials with success and clinically meaningful benefit. Li…
RT @HenryMuney: Neuro-oncologist Linda Liau, MD, PhD, MBA led brain tumor vaccine trials with success and clinically meaningful benefit. Li…
$nwbo
RT @HenryMuney: Neuro-oncologist Linda Liau, MD, PhD, MBA led brain tumor vaccine trials with success and clinically meaningful benefit. Li…
Dr. Linda Liau https://t.co/F3W3UYnnZb Enough said.
RT @HenryMuney: Neuro-oncologist Linda Liau, MD, PhD, MBA led brain tumor vaccine trials with success and clinically meaningful benefit. Li…